These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 21070456)
1. A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dayan SH; Arkins JP; Patel AB; Gal TJ Dermatol Surg; 2010 Dec; 36 Suppl 4():2088-97. PubMed ID: 21070456 [TBL] [Abstract][Full Text] [Related]
2. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks? Kapoor R; Shome D; Jain V; Dikshit R Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041 [TBL] [Abstract][Full Text] [Related]
3. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Prager W; Wissmüller E; Kollhorst B; Williams S; Zschocke I Dermatol Surg; 2010 Dec; 36 Suppl 4():2155-60. PubMed ID: 21134046 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction. Sepehr A; Chauhan N; Alexander AJ; Adamson PA Aesthetic Plast Surg; 2010 Oct; 34(5):583-6. PubMed ID: 20383497 [TBL] [Abstract][Full Text] [Related]
5. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Carruthers A; Carruthers J; Monheit GD; Davis PG; Tardie G Dermatol Surg; 2010 Dec; 36 Suppl 4():2121-34. PubMed ID: 21134044 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Brandt F; O'Connell C; Cazzaniga A; Waugh JM Dermatol Surg; 2010 Dec; 36 Suppl 4():2111-8. PubMed ID: 21134043 [TBL] [Abstract][Full Text] [Related]
7. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Carruthers J; Carruthers A Dermatol Surg; 2007 Jan; 33(1 Spec No.):S10-7. PubMed ID: 17241408 [TBL] [Abstract][Full Text] [Related]
9. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Schlessinger J; Monheit G; Kane MA; Mendelsohn N Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254 [TBL] [Abstract][Full Text] [Related]
10. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes. Carruthers J; Carruthers A; Monheit GD; Davis PG Dermatol Surg; 2010 Dec; 36 Suppl 4():2135-45. PubMed ID: 21070457 [TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Fagien S; Cox SE; Finn JC; Werschler WP; Kowalski JW Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410 [TBL] [Abstract][Full Text] [Related]
12. Commentary: Efficacy and safety of a novel botulinum toxin topical gel. West TB Dermatol Surg; 2010 Dec; 36 Suppl 4():2119-20. PubMed ID: 21244565 [No Abstract] [Full Text] [Related]
13. The use of botulinum toxin type A in cosmetic facial procedures. Jaspers GW; Pijpe J; Jansma J Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695 [TBL] [Abstract][Full Text] [Related]